Cantab Biopharmaceuticals Ltd utilises its experience, knowledge and network within biopharmaceutical development to identify suitable product targets for biosuperior development.
Once a suitable target has been identified appropriate cutting-edge technology is applied, sourced either internally or through in-licencing, to address sub-optimal in-market characteristics of the originator product, therefore adding value to the asset.
Production processes and associated analytical procedures are developed rapidly and rationally using Quality by Design principles, the extensive application of Design of Experiments standards and ultra-scale-down methodologies.
CBL advances products to pre-clinical toxicology in-house and then out-sources all further stages in product development. The stage to which each product is taken before divestment is determined on a drug-by-drug basis, dependent upon the significant value points. Once the specific value point has been achieved for the asset, it is divested to an appropriate partner organisation.